SUNNYVALE, Calif., Jan. 15 /PRNewswire/ -- MRG, Inc. and Fuji-Keizai USA announce the release of a new market research study "Proteomics R&D Competition Post Genome-Project Era." This study analyzes the major market segments in the emerging field of proteomics, the global study of protein profile changes due to developmental, environmental or disease states, and its application to the drug development process.
"Proteomics is projected to grow from a $565 million market in 2001 to over $3.3 billion in 2006, representing over 40% average annual growth rate," states Analyst Elaine Mansfield, Ph.D., the main author of the study. "One of the primary driving forces of this growth trend is the need to increase the return on investment in pharmaceutical R&D."
The Pharmaceutical industry is the most profitable sector of the Fortune 500 with average profits in excess of 18% of revenues, or almost three times higher than other industries. However, the high cost of R&D, intense competition, long lead times in development, and short patent protection periods are putting increasing pressures on Pharmaceutical executives to find more efficient discovery platforms and development paradigms.
The advent of combinatorial chemistry, genomics, and gene expression profiling with DNA biochips has led to more and more compounds and gene targets than ever before. "To streamline product development, more efficient methods to validate chemical lead compounds are needed," states Mansfield. "This is where the emerging proteomics platforms profiled in the market study will play a key role."
The report analyzes seven market segments, including Emerging Proteomics Technologies, Proteomics Chip Providers, Proteomics Platform Providers, Reagent or Antibody Providers, Proteomics Informatics Tools and Database Providers, Proteomic Service Providers, and Proteomics-based Drug Discovery Companies. The report also includes analysis of over 190 strategic alliances among the companies analyzed, as well as 50 in-depth profiles of Proteomics companies. Examples of companies profiled in the report are Iconix, Incyte, Celera Genomics, Oxford GlycoSciences, Zyomyx, Celera, SomaLogic, Ciphergen, Phylos, Affibody, and NeoGenesis.
This 160-page report is available in an English or Japanese-language edition for US $1,495.00 each. To order or request information, contact Veronica Phanthavong at 408-524-9767 or info@mrgco.com. Visit MRG at www.mrgco.com. |
